The Antimicrobial-Resistance “Trial Deficit” in Africa, Re-examined: Why the Headline Statistic Fails and What the Real Gap Is

Antimicrobial Resistance Crisis

Abstract

Correction (Version 2 — 10 July 2026): The original article's central thesis — that Africa suffers a structural antimicrobial-resistance (AMR) “trial deficit”, evidenced by AMR being only ~0.2% (“virtually 0%”) of African trials — is WITHDRAWN as a denominator artifact. Recomputed from ClinicalTrials.gov/AACT, African sites host 18.15% of AMR-condition trials, which is 4.2× the 4.33% baseline African share of all trials: Africa is over-represented, not under-represented, on this metric, and at near parity once adjusted for AMR burden (18.8 vs 20.4 trials per 100,000 attributable deaths). In addition, 8 of 9 checkable reference PMIDs in the original pointed to unrelated papers and have been corrected. Corrected finding: the genuine problem is a global scarcity of AMR trials relative to burden, plus the absence of novel-agent trials at African sites and concentration in South Africa/MDR-TB.

Background. Africa carries a heavy antimicrobial-resistance (AMR) burden, and the original analysis argued that a "0.2% AMR trial share" evidences a structural African trial deficit. We test that claim reproducibly.

Methods. AMR-condition trials were recomputed from the AACT April-12-2026 snapshot (reusable `_africa_equity_verify.py`), and like-for-like plus burden-adjusted comparisons were derived (`54-amr-crisis-verify.py`). Burden anchors were taken from the PubMed-verified GRAM global (Murray 2022) and WHO African-region (Sartorius 2024) analyses. Every PMID was re-verified.

Results. African sites host 47 of 259 AMR-condition trials (18.15%), 4.2× the 4.33% baseline African trial share; interventional 31/162 (19.14%). AMR is 0.19% of African trials but only 0.045% of global trials (a 4.2× higher Africa fraction). Burden-adjusted, Africa runs 18.8 vs the global 20.4 AMR trials per 100,000 attributable AMR deaths — near parity. WHO African-region 2019 burden: 250,000 attributable / 1.05 million associated deaths (Sartorius 2024), against a global 1.27 million attributable (Murray 2022). What survives as real: the AMR trial enterprise is tiny relative to burden everywhere; novel-agent (cefiderocol, ceftazidime-avibactam, imipenem-relebactam) trials at African sites are absent; African AMR trials concentrate in South Africa and MDR-TB.

Conclusion. Africa is not specifically under-represented in AMR trials on any like-for-like or burden-adjusted metric. The genuine crisis is a global scarcity of AMR trials relative to burden, plus specific gaps in novel-agent evaluation and geographic breadth — a more defensible and more actionable framing than the withdrawn "0.2% deficit."

---